Glenmark Pharmaceuticals reported a net profit of ₹347.9 crore for the third quarter of fiscal year 2025, recovering from a net loss of ₹351.3 crore in the same period last year. Revenue from operations rose by 35.1% to ₹3,387.6 crore, compared to ₹2,506.7 crore in the corresponding quarter of the previous fiscal year. The company maintained its fiscal year 2025 guidance for both revenue and margin, targeting a margin of 19% and a domestic revenue growth of 9-10%. In a recent conference call, Glenmark's management indicated that the margin for the first nine months of FY25 was 18% and projected an improvement of 1-1.5% for FY26. However, the company also disclosed that the U.S. Food and Drug Administration (USFDA) issued five observations regarding its Indore facility. Meanwhile, Glenmark's shares rose by 4% following the Q3 results and guidance announcements.